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PENAMBAHBAIKAN PENGHASILAN LOVASTATIN OLEH Fusarium 
pseudocircinatum IBRL B3-4 MELALUI FERMENTASI 
SUBSTRAT PEPEJAL 
 
ABSTRAK 
Keupayaan bran beras dan beras perang dalam menurunkan kolesterol dan 
menyokong sistem fermentasi substrat pepejal (SSF) tidak dapat dinafikan. 
Tambahan pula, kemudahan untuk mendapatkan substrat-substrat tersebut di kilang 
adalah mudah serta harga yang tidak mahal. Sejak beberapa tahun yang lepas, 
penyelidik-penyelidik telah mengkaji keupayaan padi serta komponennya yang lain 
seperti bran, beras, jerami dan juga sekam, mempunyai kebolehan dalam 
menghasilkan metabolit sekunder termasuklah statin. Hospital tempatan di Malaysia 
mendapat permintaan yang tinggi terhadap statin dan pengambilan lovastatin adalah 
yang paling ketara di mana sebanyak 51% preskripsi telah dibuat kepada pesakit-
pesakit berkolesterol tinggi. Maka, kajian ini menekankan kepada penambahbaikan 
penghasilan lovastatin oleh Fusarium pseudocircinatum IBRL B3-4 melalui SSF. 
Bran beras dan beras perang memberikan nilai komposisi berbeza terhadap 
kelembapan, protein, lipid, fiber, karbohidrat dan abu. Komponen tertinggi yang 
didapati dalam bran beras adalah karbohidrat iaitu sebanyak 41.20 ± 2.10% 
manakala fiber memonopoli komposisi beras perang (48.53 ± 0.58%). Daripada 
jumlah 78 kulat berfilamen, 55 pencilan menunjukkan titik gelap yang positif di atas 
plat kromatografi lapisan nipis (TLC) dengan faktor pengekalan (Rf) antara 0.26 
hingga 0.32. Walau bagaimanapun, hanya 28 pencilan kulat telah dikesan 
mensintesiskan lovastatin melalui menerusi sistem kromatografi cecair berprestasi 
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tinggi (HPLC). Pencilan IBRL B3-4 menunjukkan penghasilan lovastatin tertinggi 
berjumlah 281.67 ± 44.44 µg lovastatin/g. Berdasarkan morfologi koloni dan 
struktur pada agar kentang dektrosa (PDA), koloni pencilan IBRL B3-4 tumbuh 
sehingga 54 mm dan 60 mm masing-masing di bawah keadaan gelap dan bercahaya. 
Untuk penelitian struktur di atas agar bunga teluki (CLA) dan agar Spezieller 
Nahrstoffarmer (SNA), pencilan tersebut mempunyai mikrokonidia berbentuk bujur 
(4.5-7.0 x 1.7-2.6 µm), makrokonidia yang melengkuk serta berbentuk sabit (32.0-
46.4 x 1.2-2.9 µm), kepala palsu, hifa berlingkar serta rantaian pendek. Melalui 
pendekatan molekular pula, pencilan ini memberikan persamaan urutan sebanyak 
99.33% (pangkalan data Fusarium-ID) dan 99.00% (pangkalan data GenBank) 
dengan F. pseudocircinatum. Kondisi terbaik bagi F. pseudocircinatum IBRL B3-4 
untuk menghasilkan lovastatin dalam sistem kelalang adalah menggunakan saiz asal 
substrat, kandungan kelembapan sebanyak 70% (i/b), suhu pengeraman pada 30 ± 
2°C, saiz inokulum 1 x 10
5
 spora/mL, pH 6.5, 5 g kuantiti substrat (nisbah 1:1) 
dengan keadaan statik tanpa pengadukan. Sistem ini juga memerlukan nutrisi 
tambahan iaitu 1.5% (b/b) sukrosa, 1% (b/b) ekstrak yis dan 0.5% (b/b) kalsium 
klorida. Sistem dulang juga memerlukan kondisi yang hampir sama dengan sistem 
kelalang kecuali kandungan kelembapan (60%; i/b) dan kuantiti substrat (100 g atau 
ketebalan 0.5 cm). Produktiviti akhir yang dikesan daripada sistem kelalang ialah 
1770.00 ± 60.00 µg lovastatin/g pepejal kering manakala dalam sistem dulang pula 
sebanyak 2436.67 ± 15.56 µg lovastatin/g pepejal kering, mewakili 38% 
peningkatan. Kedua-dua sistem memerlukan 12 hari untuk mencapai produktiviti 
yang maksima. Semasa penelitian toksin kulat, F. pseudocircinatum IBRL B3-4 
telah mensintesiskan moniliformin (MON) dan fumonisin B1 (FUM B1) masing-
masing sebanyak 4.20 ± 1.12 µg MON/g substrat and 1.73 ± 0.71 µg FUM/g 
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substrat. Walau bagaimanapun, nilai kepekatan maut 50% (LC50) untuk fraksi 
lovastatin menunjukkan aktiviti tidak toksik kerana nilai tersebut melebihi 1 mg/mL. 
Sepanjang 4 minggu, fraksi lovastatin berkepekatan 110 mg sampel fraksi/kg berat 
badan (yang mewakili 550 to 750 µg lovastatin/g berat kering lovastatin) 
memberikan dos terbaik untuk merendahkan lipoprotein ketumpatan rendah (LDL) 
dan meningkatkan lipoprotein ketumpatan tinggi (HDL) dalam tikus jantan dan 
betina Sprague dawley. Nilai akhir LDL yang dikesan melalui pembaca mikroplat 
Termo Saintifik Multiskan® Spektrum ialah 0.006 ± 0.001 µg/µL and 0.004 ± 0.001 
µg/µL, masing-masing untuk tikus jantan dan betina. Manakala nilai HDL pula, ia 
meningkat menjadi 0.023 ± 0.001 µg/µL (tikus jantan) dan 0.022 ± 0.003 µg/µL 
(tikus betina). Keputusan yang diperolehi daripada kajian ini mencadangkan 
penggunaan fraksi lovastatin daripada F. pseudocircinatum IBRL B3-4 sebagai agen 
merendahkan kolesterol. 
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IMPROVEMENT OF LOVASTATIN PRODUCTION by Fusarium 
pseudocircinatum IBRL B3-4 via SOLID SUBSTRATE 
FERMENTATION 
 
ABSTRACT 
The ability of rice bran and brown rice in lowering cholesterol and 
supporting solid substrate fermentation (SSF) system are undeniable. Plus, the 
accessibility for these substrates is reachable at the mill factory with inexpensive 
price. For the last few years, researchers have investigated paddy and its other 
components like bran, rice, straw and husk, own the potentiality in producing 
secondary metabolite including statin. Malaysian local hospital has experienced a 
high demand on statin and lovastatin is the most outstanding drug with 51% 
prescription done for hypercholesterolemia patients. Thus, this recent investigation 
emphasized the improvement of lovastatin production by Fusarium 
pseudocircinatum IBRL B3-4 via SSF. Rice bran and brown rice denoted different 
composition values in moisture, protein, lipid, fibre, carbohydrate and ash. The 
highest component in rice bran was carbohydrate with 41.20 ± 2.10% while fibre 
was the superior composition in brown rice (48.53 ± 0.58%). Out of 78 filamentous 
fungi, only 55 isolates displayed positive dark spot on the thin layer chromatography 
plate (TLC) with retention factor (Rf) of 0.26 to 0.32. However, only 28 fungal 
isolates were detected to synthesise lovastatin through high performance liquid 
chromatography system (HPLC). IBRL B3-4 isolate depicted the highest lovastatin 
production with 281.67 ± 44.44 µg lovastatin/g dry solid. Based on the colony and 
structural morphologies on potato dextrose agar (PDA), the colony of IBRL B3-4 
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isolate was grown to 54 mm and 60 mm under dark and light conditions, 
respectively. For structural observation on carnation leaf agar (CLA) and Spezieller 
Nahrstoffarmer agar (SNA), the isolate owned oval shape microconidia (4.5-7.0 x 
1.7-2.6 µm), slender and falcate shape macroconidia (32.0-46.4 x 1.2-2.9 µm), false 
head, coiled hyphae and also short chain structure. As a respond to the molecular 
approach, this isolate depicted 99.33% (Fusarium-ID database) and 99.00% 
(GenBank database) sequence similarity with F. pseudocircinatum. The best 
condition for F. pseudocircinatum IBRL B3-4 to produce lovastatin in the flask 
system was under the original substrate size, 70% (v/w) moisture content, incubation 
temperature of 30 ± 2°C, inoculum size of 1 x 10
5
 spore/mL, pH 6.5, 5 g of substrate 
quantity (1:1 ratio) with static condition. It also needed external nutrients namely 
1.5% (w/w) sucrose, 1% (w/w) yeast extract and 0.5% (w/w) calcium chloride. The 
tray system also required almost the same conditions with the flask system except 
for moisture content (60%; v/w) and substrate quantity (100 g or 0.5 cm thickness). 
The final productivity detected from flask system was 1770.00 ± 60.00 µg 
lovastatin/g dry solid while in tray system was 2436.67 ± 15.56 µg lovastatin/g dry 
solid, which represented 38% increment. Both systems required 12 days incubation 
period to synthesis the maximal productivity. During mycotoxin investigation, F. 
pseudocircinatum IBRL B3-4 has synthesized moniliformin (MON) and fumonisin 
B1 (FUM B1) at 4.20 ± 1.12 µg MON/g substrate and 1.73 ± 0.71 µg FUM/g 
substrate, respectively. However, the lethality concentration 50% values (LC50) for 
fractional lovastatin signified non-toxic activities as the value was higher than 1 
mg/mL. Within 4 weeks treatment, fractional lovastatin concentration of 110 mg 
fraction sample/kg body weight (which represented 550 to 750 µg lovastatin/g dry 
solid of lovastatin) was slightly the best dose to reduce the low density lipoprotein 
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(LDL) and increase the high density lipoprotein (HDL) in male and female Sprague 
dawley rats. The final LDL value detected via Thermo Scientific Multiskan® 
Spectrum microplate readers in male and female was 0.006 ± 0.001 µg/µl and 0.004 
± 0.001 µg/µl, respectively. While for the HDL, it amplified to 0.023 ± 0.001 µg/µl 
(in male) and 0.022 ± 0.003 µg/µl (in female). The results obtained from this work 
suggested the application of fractional lovastatin from F. pseudocircinatum IBRL 
B3-4 can greatly appointed this compound as an anti cholesterol lowering agent. 
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CHAPTER 1 
INTRODUCTION 
1.1 Hypercholesterolemia versus its reversal agent 
Hypercholesterolemia is an anomalous cholesterol level in blood which is out of 
normal range and regularly welcomes the cardiovascular-relating events. Any 
substances or compounds which can obstruct the extra production of cholesterol in liver 
are recognized as hypercholesterolemia agent. Cardiovascular diseases are a cluster of 
heart and blood vessel abnormalities which can be controlled by cholesterol antidotes 
like statins. Besides anticholesterol agent, statin is also well established as a stroke 
preventer and able to block the peripheral vascular disease (Maron et al., 2000). At the 
same time, it possesses biological and pleiotropic effects including antithrombotic and 
anti-inflammatory which may lead to atherosclerotic plaque reduction (Rosenson and 
Tangney 1998; Fenton and Shen 1999; Vaughan et al., 2000) and also as a treatment 
against Alzheimer disease, multiple sclerosis, hypertension, ostreoporosis, ventricular 
arrhythmia and immune response (Glorioso et al., 1999; De Sutter et al., 2000; Meier et 
al., 2000; Chong et al., 2001; Zamvil and Steinmann, 2002; Eckert et al., 2005). The 
controllers for the hypercholesterolemia are low density lipoprotein (LDL) and high 
density lipoprotein (HDL). Both of these carriers are responsible to translocate the 
cholesterol in blood within cell which results changes in cholesterol. 
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1.2 Fermentation and idiolites perspectives 
Fermentation is an ample process to produce complex molecules and active 
compounds such as antibiotics, enzymes, vitamins, amino and organic acid that are not 
viable to be chemically constructed (Reddy et al., 2012). It is a technique of biological 
modification of complex substrates to become simpler compounds by microorganism 
including bacteria, fungi and yeast. Apart from carbon dioxide and alcohol, the 
metabolic breakdown also releases the additional compounds which are also known as 
secondary metabolites (Subramaniyam and Vimala, 2012) or idiolites. Chemical 
structures of these metabolites are secreted by certain microbes and some plants. They 
are spawned throughout trophophase period (rapid growth phase or log phase) and are 
further synthesized at the later phase namely iodophase (stationary phase). The 
accomplishment of any biosynthesis extension in iodophase relies on the tropophase 
(Barrios-González et al., 2003). Secondary metabolism in the iodophase employs 
primary metabolites to generate species-specific and chemically vary end products that 
are not vital for microbial growth (Waites et al., 2001). The booster of secondary 
metabolite production is when the growth is restricted due to the lack of nutrients either 
carbon, nitrogen or phosphate (Barrios-Gonzales et al., 2003).  
 
1.3 Lovastatin in action 
Statins are the recommended drugs for hypercholesterolemia which are derived 
via fermentation as a secondary metabolite compound. Together with recognized diets 
and physical exercises, statins can be a navigator for the cholesterol level in blood. A 
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few statins have been manufactured as a single-ingredient products with their own 
commercial names by US Food and Drug Administration namely atorvastatin,   
fluvastatin,   lovastatin,   pitavastatin,   pravastatin,   rosuvastatin  and simvastatin 
(United State Food and Drug Administration, 2012). The standard recommended dose 
by medical practitioners was 20 to 40 mg. These drugs’ concentration can deduct LDL 
by about 25% to 40% and increase HDL nearly 5% to 10% (Scirica and Cannon, 2005). 
Lovastatin is categorized under natural statin and formerly known as mevinolin, 
monacolin K and Mevacor. This persuasive drug is responsible to demolish 3-hydroxy-
3-methyl glutaryl coenzyme A reductase (HMG CoA) which is attracted to trap at the 
early step of cholesterol biosynthesis. Due to the heat and mass transfer problems which 
occurs in solid substrate fermentation system (SSF), submerged fermentation (SmF) has 
become a favorite mediator for lovastatin production (Pandey, 2003). Nevertheless, it 
can also be generated by the emerging technology of SSF which displays more 
advantages. This system promises more biotechnological benefits over than SmF even 
in a basic laboratory scale. It offers higher fermentation yield and product concentration 
packaged with better stability, lower in catabolic suppression, sterility demand (Hölker 
et al., 2004), energy requisite, producing less dissipate water and biological friendly 
(Pandey, 2003). SSF has proven in exhibiting much distinctiveness which is indeed very 
useful and has become a major industrial microbial producer. 
Production of lovastatin by SmF and SSF has been widely investigated and 
commonly, filamentous fungi exhibit tremendous potentiality. Reports from 2003 
onwards recognized that other than Aspergillus terreus (Casas López et al., 2004; 
Pansuriya and Singhal, 2010), there are numbers of different genus or species of fungi 
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that hold abilities to generate lovastatin specifically Aspergillus niger, Fusarium sp. 
(Raghunath et al., 2012), Penicillium funiculosum (Reddy et al., 2011), Aspergillus 
fisheri (Latha et al., 2012), Monascus purpureus, Monascus ruber (Seraman et al., 
2009; Panda et al., 2010), Monascus pilosus (Miyake et al., 2006), Aspergillus flavipes 
(Valera et al., 2005), Trichoderma viridae and Trichoderma longibrachiatum (Samiee 
et al., 2003). 
 
1.4 Rationales of Study and Objectives 
Increment of hypercholesterolemia patients, high demand in statin drugs 
prescription, large capacity of agriculture wastes in Malaysia and advancement in SSF 
which can turn the waste into myriad of value added products, are the concrete 
rationales for this research. 
An outbreak of world’s bestselling drugs in 2013 which is recently highlighted 
by Forbes magazine exposes that hypercholesterolemia generic remedy namely statin, 
still holding the throne of the greatest selling drugs totaling of USD13,696 million in 
2006. Until now, the number has not yet been broken by sales of any other drugs. 
According to the World Health Organization’s report, in 2008, 30% of global deaths 
(equal to 17.3 million of people) are caused by cardiovascular diseases and 
hypercholesterolemia was the main trigger. It has been predicted that by 2030, a total 
mortality can potentially hit to 23.3 million figures (World Health Organization, 2013). 
Cardiovascular disease is one of the forefront diseases that cause death at Malaysian 
government hospitals in 2009. The report indicates a total of 55.9% of patients suffered 
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from acute coronary syndrome (ACS) due to dyslipidemia condition (an elevation of 
lipoprotein level which leads to hypercholesterolemia) (Ministry of Health Malaysia, 
2010). A local data collection of cholesterol level among Penangites at Sungai Pinang 
Township indicated 3 out of 12 persons hit the cholesterol reading of 5.2 mmol/L or 
more (Kiew and Chong, 2013). The worrisome increases after National Cardiovascular 
Disease Database Malaysia (2008) reveals that the development of ACS among 
Malaysians is at a younger age (58) compared to other countries i.e. China, Thailand 
and the West (above age of 60).  
Statins are a potent hypercholesterolemia modifying drug in Malaysia as 91% of 
discharged patients from our local hospitals have experienced the statins treatment 
(Wan Ahmad et al., 2011; Ahmad et al., 2011). The figure increases almost 19% from 
year 2007 to 2008. Among statins, lovastatin is the most outstanding drug in Malaysian 
hospitals with 51% prescription and this recent status has appointed lovastatin to be 
under top 40 most wanted drugs in this country. Since year 2007 to 2008, the demand 
towards lovastatin increased and its rank in National Cardiovascular Disease Database 
Malaysia changed from 13
th
 to 9
th
 (National Cardiovascular Disease Database Malaysia, 
2008). In 2005, the expenditure of general cholesterol lowering drug (including statin) 
was about RM108.5 million out of RM2.2 billion of total drugs expenses (Sameerah 
and Sarojini, 2007). After considering all of the provided facts, Malaysians needs to 
have a new mode of ‘drug’ to lessen the government burden and obtain the healthiness. 
One of the best solutions is by considering the traditional or staple food which owns the 
medicinal value in lowering cholesterol such as ‘Angkak’ or red yeast rice production, 
an edible traditional medicinal-food for hypercholesterolemia. The trial on rice bran and 
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brown rice in producing anticholesterol agents are rarely being investigated especially 
through solid substrate fermentation system, albeit both of these products are valuable 
of respect in their own right. Kang et al. (2012) recorded a tremendous action of rice 
bran in reducing lipid level in mice by inspecting the lipid excretion in fecal. Even in 
humans, rice bran still maintains its anticholesterol greatness by improving 78% of lipid 
ratios in hypercholesterolemia patients (Gerhardt and Gallo, 1998). Brown rice, on the 
other hand, is also bringing a parallel impact as same as rice bran. Through research, a 
brown rice diet in Sprague dawley managed to put the LDL condition at ameliorate 
level (Roohinejad et al., 2010). There was also a significant decrease in lipid activity 
after 10 days of lipid profile in rabbit as reported by Mohd Esa et al. (2011). Due to 
these consistent evidences, the rice bran and brown rice should release no doubt to be 
selected as a ruling element in SSF for the production of anticholesterol agent purpose.  
In addition, the originality of lovastatin is another selection factor for this 
experiment. It is generated naturally from the fermentation process and holds a low 
adverse side effect towards animal and human (Tobert, 2003). Up until now, only about 
4.6% of patients stop prescribing their lovastatin medicine because of the side effect 
(Goswami et al., 2012). Ever since from its first discovery until the patent approval by 
Food and Drug Administration (FDA), lovastatin is widely produced under 
fermentation process and SmF is the foremost system for its production. SmF by batch 
or fed-batch culture is the well recognized method to generate lovastatin in the system 
by diversifying the conditions of physico-nutritional parameters. The advancement in 
SmF gives another idea to develop the SSF system. Isolation, screening, optimization, 
scale up system and purification of lovastatin via SmF which including Plackett-
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Burman study, factorial designs and response surface methodology (RSM), are 
inclusively  reported by researchers (Lai et al., 2003; Seraman et al., 2010). Thus, it is 
important to initiate another research of SSF lovastatin-based.  
Agro-industry is still an important sector that contributes to Malaysia 
economical growth. In year 2013, Malaysia produced RM789.9 billion of Gross 
Domestic Product and out of the figure, RM56.9 billion representing agriculture, 
forestry and fishing sector (The Malaysian Economy in Figures, 2013). From the 
statistic, it can be concluded that agricultural (or agro-industry) waste becomes a 
troublesome burden to the government. Farmers in Malaysia habitually use an easy 
initiative method to overcome the biomass abundant (mostly paddy and oil palm’s left-
over) which is by allowing a direct open burning. Under low cost and time saving 
factors, the burning activity is done to clear the land and fertilize the soil for the next 
planting cycle. The biomass burning inspires the greenhouse gas emissions such as 
carbon dioxide, methane, carbon monoxide and nitrous oxide (N2O), into the 
atmosphere. However, carbon dioxide is the most widely produced gas from the 
combustion of biomass (Mastura, 2008). The existence of those gases contribute to the 
production of chemicals in the ozone layer (troposphere) that directly involve in 
controlling the concentration of hydroxide radicals during the regulation cycle of other 
atmospheric gases. Some of the biomass wastes or residues can naturally be used as 
fertilizer, however, it involves a long decomposition process until at a certain stage it 
can transfer into pests’ territory (Ahmad et al., 2002). Some of the damped biomasses 
such as rice bran and palm kernel cake are also being consumed by ruminant and non-
ruminant animal as a feedstuff.  
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The benefits offered by SSF specifically its high yield and concentrated final 
product with less energy requirement and effective process (Perez-Guerra et al., 2003), 
provide some promises to disentangle all of the aforementioned problems. Hence, it 
directly leads into sensible reasons to proceed this experiment. The objectives of the 
present research are; 
1. To isolate, screen and identify potential local fungi which can significantly produce 
lovastatin under SSF 
2. To improve cultural conditions and medium compositions for lovastatin production 
3. To compare lovastatin production in flask and laboratory tray systems 
4. To purify lovastatin via chromatographic purification  
5. To test the effectiveness of fractional lovastatin as cholesterol lowering agent on 
laboratory animal, Sprague dawley rats. 
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CHAPTER 2  
LITERATURE REVIEW 
2.1 Agricultural crops in Malaysia: Rice processing and its byproduct 
In a year, a total of 998 million tones of agricultural wastes are produced 
worldwide and out of the number, 1.2 million tones is represented by Malaysia alone 
(Twana and Fauziah, 2012). According to the Department of Statistic Malaysia, in 
2010, the oil palm sector conquers the landfill agricultural production with 64,282,738 
tones of fresh fruit bunches followed by paddy (2,464,831 tones), cocoa (402 tones) and 
rubber (56 tones).  
The world needs to support 600 million tones production of Oryza sativa (rice) 
yearly (Chen et al., 2012) and 150 million hectares of land area are preserved for paddy 
planting (Food and Agriculture Organization, 2004). Rice has a few layers namely hull, 
bran layer, endosperm and embryo. Once the outer layer (the hull or husk) is eradicated, 
it will expose the brown rice which is the carrier of the essential nutrients. Rice is a 
staple food for Asian but the grain polishing process has eliminated a lot of nutrients 
richness. Cleaning, hulling and post-hulling processing which cover whitening, 
polishing and grading procedures are the basic steps in rice refining (Mohd Esa et al., 
2013). Those programs destroy B1, B3 and B6 vitamins at 80%, 67% and 90%, 
respectively. Others ousted minerals are half of manganese and phosphorus with 60% 
iron and all of the dietary fiber and vital fatty acid (Babu et al., 2009). 
The main outcome of rice process is endosperm or rice with 70% production 
which excludes its minor portion (20% rice husk, 8% rice bran and 2% rice germ) 
10 
 
(Wells, 1993; de Deckere and Korver, 1996; Van Hoed et al., 2006). A hundred 
kilograms of paddy equal to 56 to 58 kg white rice, 10 to 12 kg broken rice, 18 to 20 kg 
hull or husk and 10 to 12 kg rice bran (Kahlon, 2009). Rice husk and bran are the only 
leftovers that are applied into feed formulation (Department of Veterinary Services, 
2013). 
Comparing to the white rice, brown rice is claimed to be the best rice to 
consume. Within the brown rice, there is a bran layer and it is composed of pericarp, 
seed coat, nucellus and aluerone layer (Tahira et al., 2007). Brown rice becomes the 
second choice because of low eating quality and poor in palatability. The hard and dark 
cooked grain which is originated from the bran contributes to difficulty during 
munching process. But yet, those two elements (bran and brown rice) are the best 
options for healthy diets. 
 
2.2 Cholesterol: a review 
Cholesterol is vital during essential bile acids secretion and also very low 
density lipoproteins (VLDL) production for hormone biosynthesis. Generally, it is a fat 
substance or steroid molecule which is accumulated in our blood and cells. One-third of 
body cholesterol (75%) originated via diet and the other two-thirds (25%) are naturally 
generated from intracellular precursors by organs (Albert et al., 1980; Demain 1999; 
Furberg 1999). Cholesterol comes in two main packages; the bad cholesterol LDL and 
the good cholesterol HDL. The emergence of extra LDL in blood commonly relates to 
the increasing risk of heart attack and stroke. By contrast, HDL becomes a life guard 
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against those diseases. Besides genetic heritage, lifestyle and diet, the accumulation of 
cholesterol around the arteries is also depending on age factor (Scirica and Cannon, 
2005). The animal-based food such as meats, poultry and dairy products and also some 
seafood are sources for exogenous cholesterol ingestion with 30% to 75% naturally 
absorbed by human body. For endogenous synthesis, it takes place in liver and spares 
600 to 1000 mg/day cholesterol for our body usage. About 750 to 1250 mg cholesterol 
are secreted each day in bile. Generally, cholesterol and other fats cannot directly 
suspend in blood. Thus, it has to be carried by its own transporter, HDL and LDL. In 
vivo, cholesterol synthesis is triggered from acetyl CoA, reacts with acetoacetyl CoA to 
form HMG CoA and then it is narrowed down to mevalonate with HMG CoA reductase 
intervention (Campbell and Farrel, 2008). During this rate limiting step, the invading of 
cholesterol inhibitors such as statins are very crucial in controlling cholesterol over 
production. 
 
2.2.1 Biomedical applications of lovastatin 
Cholesterol obstruction by lovastatin not only works on hypercholesterolemia 
but also in other clinical terms. The trafficking condition during or after the elimination 
of HMG CoA reductase in cholesterol biosynthesis pathway (specifically in mevalonate 
pathway) allows bunch of mystifying pathways with unknown mechanisms system that 
might spare a lot of advantages in healing other chronic diseases.  
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2.2.1.1 The triumph of lovastatin in heart diseases 
Human heart is a pump that comprises four chambers with remarkable ‘lup-dup’ 
rhythm, symbolic of the opening and closing of its valves. A complete blood pumping 
travels from right ventricle to left ventricle via pulmonary artery and pulmonary vein 
and finally, the oxygenated blood will be transported throughout the body by arteries. 
This tremendous process repeats around 72 times in a minute, more than 100,000 times 
daily, over 37 million times yearly and almost 3 billion times in a lifetime. 
Approximately, the human heart pumps 4,000 gallons of blood per day. The hard work 
of heart may welcome variety of diseases and usually the blood vessels become the 
main factor of the problematic compare with the heart itself. The failure of coronary 
arteries to transport blood and oxygen required by the heart muscle is defined as 
coronary heart disease and the most widespread cause of this disease is atherosclerosis. 
The event happens due to the plaque attachment to the coronary arteries wall and 
obstructs the blood flow. The plaque is built of cholesterol deposit, calcium and 
anomalous cells (Pampel and Pauley, 2004). The lovastatin intakes can increase the 
good cholesterol level (HDL) in blood system which leads into lesion retardation 
around the artery. Furthermore, it is also believed to cure all kinds artery related 
problems including improvement of endothelial function, controlling the inflammatory 
responses, sustaining plaque constancy and averting thrombus development 
(Sreenivasan et al., 2008).  
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2.3 Statins 
2.3.1 Back to the past: the historical statins 
Akira Endo is the best person to enlighten the discovery of statins. In 1971, a 
research team was set up to isolate fungi and mushrooms. Within two years, they 
managed to identify Penicillium citrinum ML-236B as a mevastatin or compactin 
producer, an inhibitor for lipid secretion. Pioneering in statin group, mevastatin 
scientifically denoted a reduction of plasma cholesterol in hens, dogs and monkeys. 
However, Japan stopped the trial because of the tumor detection in dogs. The next 
finding is a ‘controversy’ lovastatin. In Tokyo (February 1979), Endo has isolated 
mevastatin analogues from Monascus ruber namely monacolin K, monacolin J and also 
monacolin L. Within those compounds, monacolin K generated the major product and 
vaguely indicated better result in demolishing HMG CoA reductase compared with the 
original mevastatin. Those three derivatives (monacolin K, monacolin J and monacolin 
L) are patented by the owner in February, April and October 1979, respectively (Endo, 
2004). Meanwhile, in 1978, Alfred Alberts and Julie Chen from Merck Research 
Laboratory found a new soil fungus, Aspergillus terreus which can also produced HMG 
CoA inhibitor. They called it mevinolin but later it is officially launched as lovastatin 
(Tobert, 2003). Merck formally patented mevinolin in June 1979 and four months later, 
it is verified that monacolin K and mevinolin consisted the same structure. Mevinolin is 
found earlier than monacolin K (November 1978 versus February 1979), but the 
copyright was four months behind monacolin K (June 1979 versus February 1979). 
There is no toxic revealed by this compound during toxicity test on animal and via this 
result, Merck boldly continued the clinical test on hypercholesterolemia patients. The 
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trials exposed a significant drop of plasma cholesterol with slight side effects. On 
November 1986, Merck moved one step forward by submitting an application to the 
Food and Drug Administration (FDA) for lovastatin commercialization. The FDA 
committees signed an approval on 1 September 1987 with a condition. The drug can be 
prescribed to the patients only if the diet or non-pharmacological techniques can not 
lessen the overproduction of cholesterol in blood (Merck and Co., 1987). 
Basically, statins are built up of polyketide portion (hydroxyl-hexahydro 
naphthalene ring system) initiated from acetate units bonded together in a head-to-tail 
formation (Manzoni and Rollini, 2002). Native lactone (a close ring form) and β-
hydroxyl acid (open ring form) are two major forms of statins. After mevastatin failure 
(compactin) and successful medicinal effect of lovastatin, statins welcoming a new 
comer into the cluster namely simvastatin (or Synvinolin and Zocor). It contains the 
same molecular structure as lovastatin but with the additional side chain methyl group. 
Then, the world witnessed the existence of pravastatin followed by fluvastatin, 
atorvastatin, cerivastatin and recent finding in 2003, rosuvastatin. As mentioned earlier, 
statins are triggered from fermentation. Thus, all of the statins are huddled into natural, 
semisynthetic and synthetic. Mevastatin and lovastatin are certainly natural statins while 
simvastatin is categorized under semisynthetic as it is synthesized from lovastatin by 
replacing the 2-methylbutryl side chain with 2,2-dimethylbutyryl. Pravastatin undergoes 
a biological transformation from mevastatin which involves Strepromyces carbophilus 
during the process. Other new statins members such as fluvastatin, atorvastatin, 
pitavastatin and rosuvastatin are in synthetic cluster. Even statins share a general action 
mechanism and structural composition which are very identical to HMG portion, they 
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diverge in their chemical structures (Figure 2.1). These structures are very potent in 
showing affinity towards HMG CoA reductase. The differences of each statins lie in the 
hydrophobic components which covalently tie a linkage to HMG-like moiety. In 
synthetic class, they have fluorophenyl groups to link to the structure. Decalin ring 
substituent appears in naturally derived statins and a special case for pravastatin as it 
consists a hydroxyl substituent at the hexahydronaphthalene nucleus which is 
considered as hydrophilic (Nigović et al., 2012).  
 
2.3.2 Biosynthesis of lovastatin  
The IUPAC name of lovastatin is [(1S,3R,7R,8aS)-8-[2-[(2R,4R)-4-hydroxy-6-oxo-
oxan-2-yl]ethyl]-3,7- dimethyl-1,2,3,7,8,8a- hexahydronapthalen-1-yl](2S) 2-
methylbutanoate with empirical formula of C24H36O5 and 404.55 molecular weight. It is 
a white, nonhygroscopic crystalline powder which is unsolvable in water except in 
ethanol, methanol and acetonitrile (Goswami et al., 2012). Lovastatin is consumed as 
lactone prodrug which is transformed into active HMG CoA inhibitor form (hydroxyl 
acid) in the hepatocyte organ, liver. As noted above, all statins derived via acetate units 
to structure out polyketide skeleton. Lovastatin Nonketide Synthase (LNKS) and 
Lovastatin Diketide Synthase (LDKS) are two polyketides preserved for lovastatin in 
Polyketide Synthase system (Barrios-González and Miranda, 2010). By referring to 
previous study by Endo (1979), two main chains are involved to spawn monacolin K or 
lovastatin which are monacolin J and monacolin L. Figure 2.2 designates the first 
synthesised chain of monacolin L which is constituted of nine acetate molecules and 
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then it alters into monacolin J (assemble from two units of acetate and nine methionine 
units) under hydroxylation process. Monacolin J subsequently linked to methyl butryl 
CoA lovastatin which is assembled from two acetate units and one methione unit. 
Polyketide Synthase system codes the LNKS and LDKS in Aspergillus terreus with a 
few essential genes engaged; lov B, lov C, lov F and lov D. LNKS is a gene outcome of 
lov B that interacts with lov C (enoyl reductase) to perform dihydro monacolin L which 
is next synthesised into monacolin J. The other pathway to generate monacolin J is via 
LDKS system and it is a prominent key to guarantee an efficient production of 
lovastatin.   lov F  cooperated  with  lov D,  a  transesterases  enzyme,  which  allow  the 
attachment of 2-methylbutyric acid to monacolin J and proceed to the formation of 
monacolin K or lovastatin (Manzoni and Rollini, 2002; Sreevanivasan et al., 2008; 
Barrios-Gonzales and Miranda, 2010).   
 
2.3.3 Lovastatin in SSF 
 Low cost factor due to dual-duty of solid substrate (as a matrix and nutrients 
support) is the utmost reason for SSF selection. One of the ancient uses of SSF, which 
dates approximately at the first century A.D., is angkak (also known as anka or Chinese 
red rice) production by Monascus sp. At that time, in China, Angkak production was 
secretly produced. However, during Ming Dynasty (A.D 1368-1644), this medicinal-
value rice was widely published to treat a lot of diseases including colic dyspepsia, 
diarrhea, hangovers and bruised muscles. Besides, it is also consumed by Chinese to 
improve  the  blood  circulation  and   upgrading  the   spleen  and  stomach  function 
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Figure 2.1: Different structures of natural, semisynthetic and synthetic statins and its similarity with HMG portion of 
HMG CoA reductase (Manzoni and Rollini, 2002) 
HMG CoA                         Lovastatin                                 Pravastatin                                   Fluvastatin 
Rosuvastatin                              Atorvastatin                                 Simvastatin                      Pitavastatin 
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Figure 2.2: Biosynthesis pathway for lovastatin generation in simplified scheme. 
The different enzymes that impregnated their own specific genes are actively 
involved in every part of bioconversion (Manzoni and Rollini, 2002). 
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 (Arunachalam and Narmadhapriya, 2011). According to recent studies, single and co-
culture inoculation (Panda et al., 2009; Panda et al., 2010) of Monascus sp. initiates the 
activity of lovastatin which indirectly proves that Monascus sp. fronting the lovastatin 
production in SSF compared with other filamentous fungi. Szakacs et al. (1998), Valera 
et al. (2005), Wei et al. (2007), Pansuriya and Singhal (2010), Reddy et al. (2011) and 
Latha et al. (2012) are researchers who gave their efforts in investigating the best 
lovastatin producers among filamentous fungi under SSF condition. It includes the 
mutant or wild-type species of suspected fungi. Furthermore, studies on maximizing the 
production of secondary metabolite lovastatin is started to be emphasized via response 
surface methodology (RSM), Plackett-Burman, Box-Behnken factorial and as well as 
fabrication and modeling of bioreactor designs. 
 
2.4 Solid substrate fermentation (SSF) and its consideration factors 
2.4.1 Definition of SSF 
 Solid substrate fermentation is a general term in describing any fermentation 
process which involves solids including suspensions of solid particles in an unremitting 
aqueous phase and even trickle filters. Solid state fermentation is also categorized under 
solid substrate fermentation (Mitchell et al., 2006). It is characterized as growing 
microorganism on adequate moist of solid supports which are comprised of insoluble 
natural substrates and inert carriers (Hölker et al., 2004). A natural territory is created 
by allowing the absence or near absence of free water in the fermentation process 
(Pandey et al., 2000). Throughout this experiment, SSF term is used to represent solid 
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substrate fermentation. As reported by Pandey (2003), the selection of microorganism 
and substrate, physico-chemical parameters, isolation and purification of the product are 
some critical aspects that should be considered prior to SSF employment. 
 
2.4.2 Rationale of filamentous fungi selection  
Common microbes such as bacteria, yeast and fungi are capable to grow and 
conquering the solid substrate. However, the most highlighted microbe in SSF, 
especially the ones with lovastatin-producing ability, goes to fungi kingdom. By 
considering the physiological, enzymological and biochemical properties in a low water 
activity (Aw) event in SSF, filamentous fungi are the best selection compared with the 
other unicellular microorganisms (Raimbault, 1998; Pérez-Guerra et al., 2003).  
Two gigantic groups in macro fungi are Ascomycetes and Basidiomycetes. 
However, only a few of the members can synchronize their growth with SSF 
surroundings (Hölker et al., 2004). The hallmark of filamentous fungi is its special 
hyphae with enzymatic tip. The hyphae ability in elongating, branching and attacking 
the substrate has made this microorganism more superior in host colonisation and 
nutrients utilisation (Figure 2.3). After inoculation process, spores take 10 hours to 
germinate. At this time, the substrate bed has to supply some heat to make sure a precise 
temperature for smooth germination. This progress results in daughter hyphae 
production which induces new branches and finally expanding the micro colony. 
Elongation of hyphae stimulates the micro colonies meeting which welcome a negative 
interaction between hyphae tips. Such this incident forces the tips to change their route  
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Figure 2.3: The illustrations of filamentous fungi growth invading the substrate 
matrix during fermentation process (Rahardjo et al., 2006). 
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or retarding the growth. For those that keep on extending, they can choose to grow at 
the surface of the liquid film or injecting into the matrices (Mitchell et al., 2006). 
Hyphae are grown in linear and constant pattern to permit a contact to the cell wall of 
solid substrate. Once it grips the substrate, the hyphal apex emits an amount of 
hydrolytic enzyme to ensure a smooth penetration into the substrate. Unlike SmF, the 
enzyme excretion in SSF is more concentrate and contribute a lot in penetration 
efficiency.  Other than invading the host, a close connection between  hyphae  and 
substrate also encourage biological synthesis and fungal metabolic activities 
(Raimbault, 1998) like secondary metabolites production. 
 
2.4.2.1 Fusarium sp. and its major mycotoxins 
This genus is defined as plant destructor with pan-tropical distribution via air, 
seeds, soils or plant debris. Commonly, the members of this genus are actively 
contributed in economic losses involving cereal grains (Goswami and Kistler, 2004), 
vascular wilts on banana (Liew et al., 1998), bakanae on rice (Nur Ain Izzati, 2007), 
pokkah boeng on sugarcane (Siti Nordahliawate, 2007), root rots on vegetable such as 
asparagus (Al-Amodi and Salleh, 2005) and some researchers reported cankers 
production on soft and hardwood trees (Wingfield et al., 2008). 
This species is literally divided into three clades; African, American and Asian. 
According to the hypothesis of O’Donnell et al. (1998), the originality of fungi host 
including its evolvement should be taking into account during clade clustering. 
However, numbers of species composition does not suit with the hypothesis. Among 
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these three groups, African is announced as the biggest clade which has 23 phylogenetic 
lineages and it huddles as productive chlamydospore-formers. The so-called ‘American 
clade’ has 18 phylogenetic lineages while the Asian is the smallest clade with 10 
phylogenetic lineages (Kvas et al., 2009).   
Mycotoxins are classified as unavoidable natural contamination in most of foods 
and feeds. Fumonisins (FUM), zearalenone (ZEN), moniliformin (MON) and 
beauvericin (BEA) are the most regular toxins produced by Fusarium sp. (Logrieco et 
al., 2002; Leslie et al., 2004; Sopterean and Puia 2012). The sodium or potassium salt 
of 1-hydroxycyclobut-1-ene-3,4-dione (Figure 2.4) is the precise criterion to elaborate 
moniliformin  (MON).  Its first outbreak  was in  1973 after the extraction process of   
F. proliferatum which was inoculated in a corn culture. However, the identified species 
shown a similar characteristic with F. moniliforme, thus the mycologists came out with 
moniliformin name (Cole et al., 1973). At least 30 Fusarium species produce this 
compound in the cereal grains (commonly corn) and the most influential species are F. 
proliferatum and F. subglutinans. 
 
 
 
 
Figure 2.4: The skeleton structure of moniliformin (sodium salt) (Munimbazi and 
Bullerman, 2001) 
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This metabolite is very toxic either to plants or animals. The symptoms of 
afflicted animal may be varied and commonly muscular failing, respiratory suffering, 
cyanosis, coma and also death, are the ordinary signs. Analyte that contains 
moniliformin has to go through cleanup process before it is further analysed via liquid 
chromatography, capillary electrophoresis or immunochemical reactions (Munimbazi 
and Bullerman, 2001). 
Fumonisin is named after F. verticilloides which previously known as F. 
moniliforme. It comprises B1, B2 and B3 and commonly B1 is found at the highest level 
compared with others (Marasas, 1996). (Rheeder et al., 2002). Approximately, 70 to 
80% of the total fumonisins are represented by FUMB1 and FUMB2 reaches up 15 to 
25%. The FUMB3 produces the lowest level which is around 3 to 8%. These 
percentages occur in solid or liquid medium condition (Branham and Plattner, 1993; 
Marín et al., 1995). Fumonisin B2 (FUMB2) and fumonisin B3 (FUMB3) show up after 
the finding of FUMB1 in 1988. The backbone of FUMB2 and FUMB3 are lacked in free 
hydroxyl groups compared with FUMB1 (Figure 2.5) (Plattner et al., 1992). 
The detection of FUMB1 in a sample usually is done via liquid chromatography 
(LC) completed with fluorescence detector. This toxin contains a least UV-light 
absorbing chromophore and has no fluorescence production because of the simple long 
chain alcohols, thus a derivatization of the free amine is required for detection purpose 
(Shephard et al., 1990; Kedera et al., 1999). 
There are a few of diseases related to fumonisins such as leukoencephalomalacia 
(ELEM), pulmonary oedema syndrome (PES) and hepatocarcinoma. These diseases 
